Business Context and Reporting Period
Company: Madrigal Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2022
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement) with Hercules Capital, Inc. and other lenders.
Key Financial Metrics and Transaction Details
- Total Facility Size: $250.0 million in term loans available in four tranches.
- Initial Draw: $50.0 million drawn at closing.
- Interest Rate: Variable rate, greater of (Prime Rate + 3.95%) or 7.45% floor. Initial rate set at 7.95%.
- Maturity Date: June 1, 2026 (extendable to 2027 upon achieving specific milestones).
- Repayment Terms: Interest-only payments until November 1, 2024 (extendable based on milestones).
- Facility Charges: $325,000 paid for the initial tranche; 0.50% of principal for future tranches.
- Equity Component: Warrants issued to lenders to acquire 2.0% of funded principal value at an exercise price of $67.12 per share (14,899 shares issued for the initial $50M).
Material Changes and Milestone Triggers
The filing details a new debt facility structured around clinical and regulatory milestones rather than immediate full funding:
- Tranche 2 ($50.0M): Available upon achievement of a pivotal Phase 3 clinical development milestone (expected Q4 2022).
- Tranche 3 ($75.0M): Available upon FDA approval for resmetirom.
- Tranche 4 ($75.0M): Available at the sole discretion of Hercules.
- Prepayment Penalties: 2.0% (first 12 months), 1.5% (13-24 months), 0.5% (25-36 months). No penalty after 36 months.
Covenants, Risks, and Management Commentary
- Financial Covenants: Commence January 1, 2023. Includes a minimum cash covenant of $35.0 million and a potential revenue-based covenant effective after September 30, 2024 (waivable if market cap exceeds $1.2 billion or specific cash ratios are met).
- Security: Obligations secured by substantially all assets except intellectual property.
- Default Provisions: Failure to achieve clinical or approval milestones does not constitute a "Material Adverse Effect" or event of default.
- Restrictions: Limitations on indebtedness, liens, investments, distributions, and mergers/acquisitions.
Investor Verification Checklist
- Verify the exact definition of the "Clinical Milestone" and "Approval Milestone" in the full Loan Agreement.
- Confirm the current cash position relative to the $35.0 million minimum cash covenant effective January 1, 2023.
- Review the dilution impact of the warrants (14,899 shares initially) and potential future warrant issuances upon additional draws.
- Monitor the timeline for the pivotal Phase 3 top-line announcement expected in Q4 2022 to trigger the second tranche.
- Assess the impact of the 7.95% initial interest rate on future cash flow projections.